

BIOME | AUSTRALIA
GROUP

The Microbiome Health Company



BIOME | AUSTRALIA GROUP

Biome aims to improve the health and quality of life of people worldwide suffering from common and chronic health conditions using evidence-based complementary medicines. As a microbiome health company driven by science, Biome operates at the intersection of natural medicine and pharmaceutical science, developing, licensing, commercialising, and marketing innovative therapeutic solutions supported by rigorous clinical research.

In partnership with leading global organisations in microbiome research and development, Biome has created two complementary therapeutic platforms with innovative delivery technologies that improve stability and efficacy. Activated Probiotics, the company's flagship range of live biotherapeutics, targets specific health conditions through clinically-validated probiotic strains. Activated Therapeutics expands treatment possibilities beyond traditional probiotics, incorporating prebiotics, postbiotics, and complementary bioactive compounds.

Supported by clinical research, including randomised, double-blind, placebo-controlled trials, these therapeutic ranges address diverse health concerns spanning digestive health, immune function, cardiovascular health, women's health, mood and sleep, bone density, and dermatological conditions. Through practitioner-only distribution across domestic and international markets, Biome educates healthcare professionals on the systemic health effects of microbiome science, providing evidence-based therapeutic tools for managing humanity's most prevalent chronic health challenges.

Acknowledgement of Country

We acknowledge the Wurundjeri people as the Traditional Owners on whose Country we are based. We pay respect to their Elders past, present and emerging and acknowledge their continuing connection to land, sea and community. We extend that respect to Traditional Owners throughout Australia where we work and operate.

Company Overview

Company timeline	04
Microbiome science	06
Letter to shareholders	08
Product research and development	10
Education and professional development	12
Brand growth and marketing strategy	14
Sales performance and distribution expansion	16
International market update	18

Annual Financial Statements

Directors' report	22
Auditor's independence declaration	35
Statement of profit or loss and other comprehensive income	36
Statement of financial position	37
Statement of changes in equity	38
Statement of cash flows	39
Notes to the financial statements	42
Consolidated entity disclosure statement	58
Directors' declaration	59
Independent auditor's report to the members of Biome Australia Limited	60
Corporate governance summary	63
Shareholder information	66
Corporate directory	69

2018

JULY
Biome Australia founded

6 employees



NOVEMBER
Activated Probiotics® launch

Biome launches its condition-specific probiotic range

2020

JUNE
TerryWhite Chemmart distribution deal

Activated Probiotics launches nationally with TerryWhite Chemmart \$833k FY20 sales revenue



NOVEMBER
UK practitioner market launch

Activated Probiotics launches into the UK Practitioner market



MARCH
Biome reaches cashflow and EBITDA positive milestones

5000 Distribution points

2024

JANUARY
UK/Ireland health retail launch

Activated Probiotics launches into UK/Ireland Health Retail

JUNE
\$7.23m FY23 Sales revenue

2023

MARCH
Biome Lift™ clinical trial preliminary results

On patients with subthreshold depression



MAY
Initial products listed with Health Canada



JUNE
\$13.01m FY24 sales revenue



SEPTEMBER
Test market launch into Canada

NOVEMBER
Canadian Health retail launches

2021



JANUARY

Biome Osteo™ clinical trial

Probone21 clinical trial using Biome Osteo™ commences in partnership with La Trobe University and Probi AB



FEBRUARY

Biome Daily Kids™ clinical trial

Biome Daily Kids™ clinical trial commences in partnership with Federation University



MARCH

Biome Lift™ clinical trial

In partnership with La Trobe University and Probiological S.p.A.

2000 Distribution points



SEPTEMBER

Priceline Pharmacy Activated Probiotics® product launch

2022

JUNE

**\$4.12m FY22 sales revenue
3000 Distribution points**



NOVEMBER

B Corporation certification

JUNE

\$2.32M FY21 Sales revenue



DECEMBER

Novel probiotic strain

Biome secures new novel probiotic strain BMB18

2025

MARCH

BMB18 successfully completes in vitro clinical study

JUNE

International pharmacy launch

Activated Probiotics launched with Uniphar pharmacy wholesale in Ireland and Propharma pharmacy wholesale in New Zealand



JUNE

Biome reaches first net profit


Activated Therapeutics® launch

New brand and range of targeted therapeutics offering natural options for common health concerns



Transforming healthcare through microbiome science

Biome is helping Australians improve their health by harnessing cutting-edge microbiome research to develop targeted, evidence-based therapeutic solutions. Operating at the forefront of where microbiome science meets clinical practice, Biome is committed to developing innovative approaches that support gut health and overall wellbeing.



Understanding the microbiome

The human gut hosts a complex ecosystem of trillions of microorganisms that function as a metabolically active organ system. This internal ecosystem doesn't just aid digestion—it orchestrates communication networks that influence a range of different bodily processes, including immunity, hormone production, neurological function, and systemic inflammation throughout the body.

When this ecosystem thrives in balance, it supports optimal whole body health. However, modern life has created widespread microbiome disruption, with compromised gut communities now linked to an expanding spectrum of chronic conditions—from metabolic disorders and autoimmune diseases to mood disturbances and skin conditions.¹

Contemporary lifestyle factors have fundamentally altered our internal microbial landscape. Ultra-processed foods, chronic stress, sedentary behavior, and frequent antibiotic exposure have collectively diminished microbial diversity and shifted gut composition toward inflammatory profiles.

This disruption manifests as compromised intestinal barrier function, allowing microbial fragments to trigger systemic immune activation. The resulting

chronic inflammatory cascade spreads beyond the gut, contributing to the rising prevalence of multisystem disorders that define modern healthcare challenges.

Targeted products for targeted outcomes

Biome has developed two complementary therapeutic ranges that help to address different aspects of microbiome health.

Activated Probiotics® is a range of precision probiotics, with each product formulated to address specific health concerns through evidence-based strain selection.

Activated Therapeutics® is comprised of evidence-based nutraceuticals and complementary medicines beyond probiotics, incorporating prebiotic fibers, postbiotic compounds, and synbiotic formulations that support microbiome health in their own unique ways.

Together, these ranges provide healthcare practitioners with comprehensive tools to improve the management of key public health concerns through targeted microbiome-based interventions.

¹ Anwar, H., Irfan, S., Hussain, G., Naeem Faisal, M., Muzaffar, H., Mustafa, I., Mukhtar, I., Malik, S., & Irfan Ullah, M. (2020). Gut Microbiome: A New Organ System in Body. In Parasitology and Microbiology Research (pp. 1-20). IntechOpen.

Letter to shareholders

Dear fellow shareholders,

The Managing Director and Company Chair are pleased to present Biome Australia's FY25 Annual Report.

FY25 was a breakout year for Biome, delivering exceptional growth across all key metrics while achieving a historic milestone—our first full year of net profit since the company's founding in 2018. This achievement, combined with our sixth consecutive quarter of positive EBITDA (excluding share based payments) and full-year EBITDA exceeding \$931,050, demonstrates the maturity and sustainability of our business model. We maintained our strong gross margin of 61.1% throughout FY25, reflecting the premium positioning and value proposition of our products.

Our annual sales revenue reached a record \$18.42 million, representing 41.6% growth versus the previous corresponding period and significantly outpacing category growth by 7–10 times. This performance was underpinned by our strongest quarter to date in Q4 FY25, with sales revenue exceeding \$5 million and culminating in a record monthly performance of \$2.1 million in June. As we enter FY26, Biome has achieved an annualised sales revenue run rate of over \$20 million, positioning us strongly to meet our Vision 27 forecast of achieving at least \$75 million in cumulative sales for FY25–27.

The results achieved throughout FY25 reflect the strength of our Activated Probiotics brand, which has now secured the number two position in total probiotic revenue within community pharmacy. Our domestic business sell-through increased by over 50% in FY25, solidifying our status as the category's leading growth brand. This outstanding performance was delivered through our continued commitment to providing industry-leading customer service, support, and education rather than relying on traditional discount models.

As a leader in clinically proven probiotics, we have maintained our unique value proposition for distribution partners in community pharmacy and independent practitioners. The consistent feedback from the

trade on successful patient outcomes continues to reinforce our business model and validates our research-driven approach to product development.

FY25 marked a pivotal year for Biome's international expansion strategy, delivering \$1.5 million in international sales revenue, representing 69% growth versus the previous corresponding period. Through extensive setup, recruitment, and business development activities across Canada, Ireland, United Kingdom and New Zealand, we have successfully secured transformational distribution partnerships that position us for significant international growth in FY26 and beyond.

Our strategic approach of establishing dedicated sales teams in each key international market, supported by our Australian head office, has proven highly effective. In Canada, initial demand for Activated Probiotics has surpassed expectations, leading to successful launches with major health retail outlets including Pure Pharmacy Group, Healthy Planet Group, Nature's Emporium, and Nature's Signature. We have also secured strong initial orders from the Canadian practitioner market and recruited our first two sales and education team members to support continued growth.

In our European markets, we secured a major distribution agreement with Uniphar in Ireland, a pharmaceutical wholesaler serving over 1,400 pharmacy customers, facilitating immediate launch into several leading pharmacy chains. Our UK business continues to expand through established health food and practitioner distribution partners, with recent launches including Planet Organic.

Our New Zealand expansion achieved a significant milestone with a new distribution partnership with Propharma, the country's largest pharmacy wholesale network and a subsidiary of EBOS Group. This collaboration, combined with our established independent practitioner market, will enable us to reach most community pharmacies across New Zealand in the coming years.

These strategic partnerships across three key international markets provide access to thousands of additional pharmacy and health food locations, establishing the foundation for substantial international growth throughout FY26 and supporting our long-term Vision 27 objectives.

Research and development remains the cornerstone of Biome's competitive advantage. A transformational highlight of FY25 was the launch of our new brand, Activated Therapeutics, marking a significant evolution in our therapeutic offering. This new practitioner-only range launched with four specialised products — Oestro-ISO

for perimenopause symptoms, Synbio-GOS for gastrointestinal repair, Pepti-BIOTIC for acid reflux, and Macro-PRO for weight management and nutritional support including for people taking GLP-1 agonist medications.. Each product is formulated with natural ingredients with specific evidence-based therapeutic applications, enabling us to broaden our mission of preventing disease and improving health outcomes to a wider range of patients seeking natural solutions.

Activated Therapeutics represents our continued commitment to evidence-based, microbiome-centered innovation, leveraging our expertise in the health effects of the gut microbiome gained through years of work in the probiotic industry. The range was immediately adopted by all key national pharmacy partners, demonstrating strong market confidence in our innovation capabilities and the quality of our product development.

Building on the clinical study completions and product launches initiated in FY24, we continue to expand our evidence base and product portfolio across both our flagship Activated Probiotics brand and our new Activated Therapeutics platform.

A major milestone for Biome during FY25 was the successful completion of our strain development program, resulting in the identification, commercial validation and characterisation of our proprietary probiotic strain *Lactobacillus plantarum* BMB18. This strain has been registered and deposited with the internationally-recognised German culture bank DSMZ, and the intellectual property has now transferred to Biome's ownership. This represents a significant step forward in IP ownership and provides us with both an owned probiotic asset and potential future licensing opportunities, creating an additional revenue stream on Biome's balance sheet.

BMB18 strengthens our commercial advantage and the uniqueness of our Activated Probiotics products by supporting future novel product development. Our intention is to leverage this proprietary strain to target health outcomes that have yet to be approached within the market, further diversifying our product portfolio and research pipeline for the coming years.

Our commitment to partnering with Australian universities and hospitals on new clinical research programs ensures a robust pipeline of innovation that will support both new applications for existing products and entirely new product categories in the years ahead.

The financial year culminated with our second Activated Probiotics Symposium, a landmark professional education event attended by hundreds of health professionals in

June. This event provided an exceptional platform to showcase our new research and production innovations, including the introduction of Activated Therapeutics, while spending valuable time with the industry's key-opinion-leading practitioners and customers. The timing of this event alongside the Activated Therapeutics launch has contributed to a strong start to FY26.

The Biome Consultative Committee, established at the close of FY24, has provided invaluable strategic guidance throughout FY25. This advisory board, comprising global leaders in probiotics manufacturing, research and development, regulatory environments, education, distribution and health, has contributed meaningfully to de-risking our growth initiatives and enhancing our international expansion capabilities.



As we look toward FY26, we are energised by the momentum built throughout FY25 and the strong foundations we have established for sustained growth. With our \$20 million annualised run rate, expanding international presence, successful launch of Activated Therapeutics across all key pharmacy partners, and continued focus on clinical innovation, Biome is exceptionally well-positioned to deliver on our Vision 27 strategic plan. Our cash position of \$2.75 million at the end of FY25, combined with positive operating cash flows, provides the financial foundation to support our ambitious growth plans while maintaining our mission to prevent disease, improve health outcomes and quality of life, and make our products accessible to all.



We want to express our sincere gratitude to our dedicated team whose commitment to excellence has delivered these outstanding results, and to our valued distribution partners who continue to trust Biome to serve their patients and customers. Most importantly, I thank you, our shareholders, for your unwavering support as we continue building Biome into a leading global player in the complementary medicines market.

We look forward to sharing further updates on our progress throughout FY26.

Blair Vega Norfolk
Managing Director

Mr Geoffrey Sam OAM
Chair

Product research and development



Over the past year, Biome has continued to invest meaningfully in research and innovation, strengthening its position as a leader in microbiome health solutions. Through a combination of evidence-based product development and continued investment in developing proprietary intellectual property (IP), Biome remains focused on delivering effective natural health solutions for healthcare practitioners and consumers alike.

Biome's focus over the past year has been to:

- Advance women's health through targeted probiotic innovations
- Broaden its therapeutic capabilities via the Activated Therapeutics range
- Develop a proprietary probiotic strain to expand future innovation capacity

Expanding support for women's health

Women's health remains the number one vitamin and dietary supplements category in Australia by sales volume.² In response to strong consumer demand for female-focused products, Biome strengthened its flagship brand Activated Probiotics with two innovative and evidence-based product launches to support women's health.

Biome Her™ Pessary

Biome Her™ Pessary provides a targeted, vaginally-inserted probiotic pessary designed for short-term use when rapid support for vaginal microbiota balance is required. This new offering perfectly complements the existing Biome Her™ Probiotic – an oral supplement for the maintenance of vaginal microbiota balance and one of Activated Probiotics' most in-demand products.

Biome Perinatal™ Probiotic

Biome addressed a growing domestic and international opportunity in the prenatal and perinatal health market with the launch of Biome Perinatal™ Probiotic, a premium formulation designed to support women's health before, during, and after pregnancy, as well as throughout breastfeeding.

Strategic launch of Activated Therapeutics

Activated Therapeutics has been created alongside Biome's flagship brand as a platform for the release of evidence-based complementary medicines and nutraceuticals beyond probiotics.

This new range enables Biome to broaden its therapeutic offering where non-probiotic solutions are best suited to address specific needs, furthering its mission to prevent disease, improve health outcomes and support more patients seeking natural health solutions.

The Activated Therapeutics range is also a reflection of the continued commitment of Biome to evidence-based, microbiome-centered innovation. Biome is leveraging its expertise in the health effects of the gut microbiome – gained through years of work in the probiotic industry – to drive product development in this new range, with a number of products incorporating microbiome-focused ingredients beyond probiotics, including prebiotics and postbiotics.

Activated Therapeutics is positioned as a practitioner-only range available via health practitioners in private practice and behind-the-counter in community pharmacy.

Meet the range

Activated Therapeutics launched with four specialised products, each containing natural ingredients selected for their evidence-based therapeutic applications to target unmet health needs.

Oestro-ISO™

Menopause symptom relief

- Standardised soy isoflavone supplement providing a clinically-backed dose for the relief of menopausal symptoms.
- Provides natural support to the 80% of women that experience symptoms during menopause and strengthens Biome's offering in the number one vitamin and dietary supplements category in Australia (women's health).



Synbio-GOS™

Gut health

- A clinically-validated synbiotic containing a specific prebiotic fibre and two probiotic strains to balance the gut microbiome and restore digestive health.
- With lower digestive issues highly prevalent and consumer satisfaction with current treatment options remaining low,³ Synbio-GOS™ is perfectly placed to address this unmet need with an evidence-based, well-tolerated formulation that can support digestive comfort across a range of different presentations.

Pepti-BIOTIC™

Heartburn support

- A postbiotic clinically studied to help reduce the severity and frequency of heartburn.
- With PPIs ranking among the most frequently prescribed medicines on the PBS,⁴ Pepti-BIOTIC™ provides a complementary approach for patients requiring additional support for heartburn management.

Macro-PRO™

Nutrition and weight management support

- A vegan formulated meal replacement with plant-based protein, organic wholefoods, 15+ vitamins and minerals, and no added sugar or vegetable oils, Macro-PRO™ is positioned as a high-quality alternative to ultra-processed meal replacements.
- Designed to help a range of different patients, including those who struggle to eat enough nutritious food (e.g. the elderly and patients experiencing side effects from GLP-1 agonist medications or bariatric surgery) and those undertaking calorie-restricted diets for weight management.

Proprietary strain development program

Biome, in collaboration with a key research partner, successfully completed the identification, commercial validation, and initial characterisation of its proprietary probiotic strain, *Lactobacillus plantarum* BMB18, in FY25.

The results of core functional characterisation studies conducted by the cell culture lab of its research partner were also received positively this year. The strain's demonstrated functional potential supports broad future health applications, with an ability to effectively:

- Modulate immune responses and inflammation
- Reduce oxidative stress
- Maintain intestinal barrier integrity

The transfer of ownership of the strain's associated IP to Biome was a significant milestone for the company this year. It represented a significant step forward in Biome's research and development strategy by:

- Strengthening its IP portfolio – established Biome's first owned probiotic strain, creating a defensible competitive advantage.
- Expanding product innovation capacity – opens the opportunity for the development of future precision probiotics targeting novel health outcomes.
- Unlocking licensing opportunities – the strain represents a potential new revenue stream via licensing agreements in global markets.

The strain is now advancing through Biome's clinical development pipeline to evaluate its efficacy in targeted condition-specific applications.

Future outlook

Biome's continued investment in product research and development over the past year has strengthened its position to better improve patient health outcomes and deliver sustainable growth.

The successful progression of BMB18 enhances Biome's long-term innovation goals, while the integration of Activated Therapeutics alongside Activated Probiotics strengthens the company's leadership in practitioner-focused and evidence-based natural health solutions.

2. Complementary Medicines Australia. (2024). 2024 Industry Snapshot. Available from: <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>

3. Royal Australian and New Zealand College of Obstetrics and Gynaecology. Clinical Guidance: Managing Menopausal Symptoms. 2020. <https://ranzocg.edu.au/wp-content/uploads/Managing-Menopausal-Symptoms.pdf>

4. Complementary Medicines Australia. (2024). 2024 Industry Snapshot. Available from: <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>

Education and professional development

Biome's Education team achieved significant milestones in FY25, strengthening the company's position as the most trusted source of microbiome and probiotic knowledge for healthcare professionals. The team of Practitioner Education Consultants (PECs) delivered comprehensive training across multiple healthcare disciplines, including pharmacists, naturopaths, dental professionals, doctors, and chiropractors.

Three strategic initiatives defined FY25 education efforts:

- International expansion through the Canadian launch of Activated Probiotics
- Thought leadership advancement via the "Changing the Script" symposium
- Therapeutic education supporting the Activated Therapeutics launch

Strategic education initiatives

Canadian market expansion

The successful launch of Activated Probiotics in Canada was supported by Biome's first North American educational initiatives, including presentations at healthcare practitioner conferences across Toronto and Vancouver. The team developed market-specific educational content for Canadian healthcare professionals, establishing a foundation for continued international growth.

Activated Probiotics Symposium

The inaugural "Changing the Script" symposium in June positioned Biome as a thought leader in microbiome science. This premium educational event brought together leading healthcare professionals to explore cutting-edge research and clinical applications.

Activated Therapeutics launch support

The Education team developed comprehensive training programs for the new Activated Therapeutics range, ensuring healthcare professionals understood the evidence base for Oestro-ISO™, Synbio-GOS™, Pepti-BIOTIC™, and Macro-PRO™.

Key educational programs

Specialised training

FY25 saw significant expansion in therapeutic education programming, with the Activated Therapeutics launch requiring comprehensive training across diverse healthcare applications. FY25 education also had a particular focus on cardiovascular health through the Biome Cholesterol™ launch. The Education team delivered targeted training to healthcare professionals on the emerging evidence for probiotic modulation of blood lipid levels, representing a new frontier in microbiome therapeutics.

Conference leadership

Biome delivered keynote presentations and educational sessions across major healthcare conferences, including NMHNZ, ACNEM, NIIM, and NAPSA Congress, reinforcing the company's expertise across diverse professional audiences.

Strategic partnerships

Key partnerships included the national Priceline pharmacist masterclass tour and collaboration with Tammy Guest at NatExpo, reaching both established practitioners and emerging healthcare professionals.



Team growth and future outlook

The Education team's enhanced capacity in FY25 enabled increased webinar delivery to professional associations, student programs, and distribution partners.

Biome's education foundation established in FY25 positions the team for continued international expansion and therapeutic range growth, maintaining the company's leadership in evidence-based microbiome education.



Brand growth and marketing strategy



Biome's education-first marketing strategy drove exceptional brand growth across all channels, positioning education as the cornerstone of sustainable competitive advantage while building trust with healthcare professionals and consumers.

Integrated marketing approach

Education remains the driving force behind Biome's marketing strategy across all channels, differentiating the company from conventional pharmaceutical marketing by prioritising knowledge transfer over traditional promotional activities. Marketing campaigns and educational programs operate as one seamless initiative, delivering high-value probiotic science education while raising awareness about product efficacy.



Professional channel excellence

Pharmacy Partnership Programs

Biome's pharmacy marketing focuses on creating deeper pharmacist-patient connections through education rather than conventional advertising approaches. The flagship Community Health Clinic program partners with community pharmacy groups to deliver free healthcare services through in-store clinics, improving health outcomes while increasing foot traffic and customer loyalty.

Practitioner education

Practitioners remain central to marketing efforts, with educational content delivered through multiple touchpoints including webinars, masterclasses, printed resources, and digital materials. The company fosters collaboration with prominent practitioners and industry associations, ensuring all content meets exceptional educational standards across publications, journals, and digital channels.



Public education impact

Biome executes two annual national Public Health Campaigns utilising mass media including broadcast video-on-demand, billboard advertising, and digital channels. This financial year, campaigns educated 5 million Australians on condition-specific probiotics and manufacturing best practices, demonstrating substantial market reach.

Ongoing consumer engagement continues through company blogs, monthly email communications, and product survey programs that maintain dialogue with end users while supporting practitioner-focused positioning.

Strategic brand positioning

The integrated education-first approach supports Biome's mission of preventing disease and improving health outcomes while positioning the company as a trusted authority in evidence-based probiotic science. This strategy creates sustainable competitive advantages through genuine expertise and trust across stakeholder groups.

The established marketing infrastructure provides scalable foundations for continued brand growth, supporting expansion into new therapeutic areas and international markets through proven educational excellence frameworks.


\$18,417,188

FY2025 Sales revenue



\$214,656
First net profit

\$1,500,000
International sales



+41%


Increase in sales revenue

64%

Compound annual growth rate

>50%

Domestic business sell-through grew by more than 50%



Annual sales revenue

Sales performance and distribution expansion

FY25 delivered exceptional sales growth and strategic distribution expansion, with Biome achieving its first full-year net profit while establishing market-leading positions domestically and securing foundations for international growth.

Revenue performance and profitability

Biome achieved a 41.6% increase in sales revenue to \$18.42 million alongside its first net profit of \$214,656, marking a significant milestone in the company's journey to sustainable profitability. The company maintained a strong compound annual growth rate (CAGR) of 64.7% for the three years ending 30 June 2025.

Gross profit climbed to \$11.25 million with margins improving to 61.1%, demonstrating operational efficiency gains and successful premium positioning. This performance included a record June quarter exceeding \$5 million in sales and six consecutive quarters of positive EBITDA.

Market leadership and key partnerships

Biome emerged as the #2 probiotics brand in Australia's community pharmacy market by total revenue (IQVIA Scan Data). Domestic sell-through increased by more than 50% in 2025, driven by strong partnerships with major retailers including Priceline Pharmacy and Terry White Chemmart.

Distribution points expanded to over 6,000 locations across Australia and New Zealand, representing a 300% increase since IPO. Activated Probiotics secured the number one growth position in community pharmacy while becoming the number two brand in total revenue within the practitioner-only and probiotics categories.

International expansion proof of concept

International sales reached \$1.5 million, up nearly 70% on the prior year, with successful market entry into Canada following positive testing results. The company secured transformational distribution partnerships with major pharmacy wholesalers including Unipharm in Ireland and Propharma in New Zealand, providing access to thousands of new outlets from FY26.

Early Canadian results are ahead of schedule, with Health Canada regulatory approval supporting market penetration across independent pharmacies, health food stores, and practitioner channels.

Product innovation and growth

The successful launch of Biome Cholesterol™ Probiotic and the Activated Therapeutics range expanded therapeutic applications and addressable markets. The company introduced six new and three renovated products during FY25, maintaining focus on evidence-based formulations while diversifying revenue streams.

Product innovation supported by proprietary IP, including the Biome's *Lactobacillus plantarum* BMB18 strain, provides competitive differentiation and future licensing opportunities.

Vision 27 strategic framework


Biome's Vision 27 strategic plan targets cumulative revenue of \$75-\$85 million over FY25-27, with the company entering 2026 reporting an annualised revenue run-rate exceeding \$20 million. The sales infrastructure and international partnerships established in FY25 provide robust foundations for achieving these ambitious growth targets across domestic and international markets.

Canada
Strong early market acceptance and significant national health retail distribution in first 12 months. Two first team members on the road supporting account development.



International market update


Biome achieved significant international expansion in FY25, with overseas sales reaching \$1.5 million, representing a 69% increase on the prior year. The company successfully entered the Canadian market following positive testing results, with early performance ahead of schedule and Health Canada regulatory approval supporting market penetration. Strategic distribution partnerships were secured with major international retailers including Uniphar in Ireland and Propharma in New Zealand, providing access to thousands of new pharmacies and health food outlets from FY26. These transformational agreements establish scalable distribution infrastructure across Canada, Ireland, the UK, and New Zealand, creating robust foundations for continued international growth while supporting Vision 27 targets.



Europe
Secured partnership with Uniphar pharmacy wholesale in Ireland. UK and Irish sales teams in place supporting account development.

Australia
Activated Probiotics® emerged as #2 probiotics brand in community pharmacy market, launched Activated Therapeutics®

Aotearoa New Zealand
Secured partnership with Propharma pharmacy wholesale and Green Cross pharmacy group



BIOME | AUSTRALIA
GROUP

Annual financial statements

Biome Australia Limited
ABN 51 627 364 014

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Biome Australia Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2025.

Directors

The following persons were directors of Biome Australia Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Mr Geoffrey Sam OAM

Chair (appointed 21 November 2024 as Non-Executive Director – 20 May 2025 appointed as Chairman)

Blair William Brabin Vega Norfolk
(Managing Director)

Dominique Gayle Fisher AM
(Independent Non-Executive Director)

Ilario Thomas Faenza
(Independent Non-Executive Chair,
resigned 20 May 2025)

Principal activities

The principal continuing activities of the Group during the financial year were developing, manufacturing and distributing innovative evidence-based products linking the gut and human health through the Group owned brand, Activated Probiotics, a first-of-its-kind range of clinically backed precision probiotics.

Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Review of operations

Biome achieved a historic milestone in FY25, delivering its first full year of net profit since the company's founding in 2018. The breakthrough year demonstrated exceptional growth across all key metrics, highlighted by annual sales revenue reaching a record \$18.4 million, representing 41% growth versus the previous corresponding period and outpacing category growth by 7-10 times.

Key Financial Highlights

The company maintained strong profitability with its sixth consecutive quarters of positive EBITDA* (*excluding share based payments), achieving full-year EBITDA* exceeding \$900,000 while preserving a robust gross margin of 61%. Q4 FY25 marked the strongest quarter to date with sales revenue surpassing \$5 million, culminating in a record monthly performance of \$2.1 million

in June. As FY26 commenced, Biome established an annualized sales revenue run rate of over \$20 million, positioning the company strategically toward its Vision 27 forecast of achieving at least \$75 million in cumulative sales for FY25–27.

The company's financial strength is further evidenced by its cash position of \$2.75 million at the end of FY25, supported by continued positive quarterly EBITDA* (*excluding share based payments) throughout the year, providing a solid foundation for ambitious growth plans.

Market Position and Growth

Biome's Activated Probiotics brand secured the number two position in total probiotic revenue within community pharmacy, with domestic business sell-through increasing by over 50% in FY25. This performance established Biome as the category's leading growth brand, achieved through industry-leading customer service rather than traditional discount models.

International Expansion

International operations delivered significant growth with \$1.5 million in international sales revenue, representing 69% growth versus the previous corresponding period. Strategic expansion across Canada, Ireland, United Kingdom, and New Zealand resulted in transformational distribution partnerships providing access to thousands of additional pharmacy and health food locations.

Key partnerships include major Canadian health retailers (Pure Pharmacy Group, Healthy Planet Group, Nature's Emporium, Nature's Signature), Unipharm in Ireland (serving over 1,400 pharmacy customers), and Propharma in New Zealand (the country's largest pharmacy wholesale network and EBOS Group subsidiary).

Innovation and Product Development

FY25 marked the launch of Activated Therapeutics, a new practitioner-only range featuring four specialised products targeting perimenopause, gastrointestinal repair, acid reflux, and weight management. The company successfully completed its strain development program, identifying and commercialising proprietary probiotic strain *Lactobacillus plantarum* BMB18, now registered with the German culture bank DSMZ and providing future licensing opportunities.

The culmination of professional education efforts included the second Activated Probiotics Symposium, attended by hundreds of health professionals, showcasing research innovations and strengthening industry relationships that contributed to a strong start for FY26.

Financial Position

The Company has \$2,746,416 in cash as at 30 June 2025 and a further \$2,094,587 in an undrawn credit facility with NAB.

The net assets of the Company increased to \$4,675,367 as at 30 June 2025 (30 June 2024: \$2,903,528) which was a result of increased capital from the exercise of company options and the Company reporting a net profit for the year.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial year.

Matters subsequent to the end of the financial year

No matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may

significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Likely developments and expected results of operations

Information on likely developments in the operations of the consolidated entity and the expected results of operations have not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the consolidated entity.

Environmental regulation

The consolidated entity is not subject to any significant environmental regulation under Australian Commonwealth or State law.

Information on directors

Name	Mr Geoffrey Sam OAM
Title	Independent Non-Executive Chair (appointed 21 November 2024)
Age	71
Qualifications	BCom (UNSW), MHA (UNSW), MA (Econ&SocStudies) (Manchester UK), FAICD
Experience and expertise	<p>Building from his background in hospital executive leadership, Geoff co-founded Healthcare Australia Pty Ltd in 2005. Healthcare Australia Pty Ltd is a privately owned healthcare company comprising a portfolio of 17 private hospitals and employing nearly 5,000 healthcare professionals nationwide.</p> <p>Geoff currently serves as a Non-Executive Director of IDT Ltd, Change Financial Ltd and EarlyPay Ltd. His past board positions include ParagonCare Ltd, Money 3 Ltd, Hutchinsons Childcare Services Ltd and Nova Health Ltd.</p> <p>With decades of executive and board-level experience in healthcare, Geoff's qualifications include a Bachelor of Commerce (Accounting and Finance, UNSW), Master of Health Administration (UNSW) and a Master of Arts (Economics and Social Studies, University of Manchester). Geoff is also a Fellow of the Australian Institute of Company Directors.</p>
Other current directorships	IDT Ltd, Change Financial Ltd and EarlyPay Ltd
Former directorships (last 3 years)	N/A
Special responsibilities	Chair of Audit & Risk Committee
Interests in shares	4,342,537 fully paid ordinary shares

Name	Mr Blair William Brabin Vega Norfolk
Title	Managing Director
Director Since	6 July 2018
Age	40
Qualifications	BCom (Accounting), MMktg (Monash), MAICD
Experience and expertise	A health industry expert with over 14 years of global pharmaceutical and nutraceutical industry experience as management and executive. Since founding the business, Blair has recruited the people, secured funding, products and IP and managed key relationships. Blair has strong relationships in media, pharmacy, research and manufacturing. Blair has a significant public profile as a health advocate and speaks at conferences and panels from mental health to general wellbeing.
Other current directorships	N/A
Former directorships (last 3 years)	N/A
Special responsibilities	Managing Director
Interests in shares	18,487,272 fully paid ordinary shares

Name	Ms Dominique Gayle Fisher AM
Title	Independent Non-executive Director
Age	68
Director since	12 August 2021
Qualifications	BA (Hons)
Experience and expertise	<p>Dominique couples her experience in tech driven businesses with a strong focus on risk mitigation and financial management which has led to her working in across a wide range of sectors in both executive and non-executive roles. Dominique has an extensive Non-Executive career, having served on ASX listed companies, IAG, Circadian Technologies/ Opthea, Pacific Brands and Trimantium GrowthOps (2 as Chair) including two IPOs (IAG and TGO); numerous private companies including NRMA, LaunchVic and SkyTechnologies.</p> <p>Dominique has extensive Audit, Remuneration and Risk Committee experience of listed and unlisted companies. Dominique has also served on various government and private advisory boards at both state and federal for both major political parties, Geoscape Australia and government agencies including the Sydney Opera House, Australia Post and the Australian Council for the Arts.</p>
Other current directorships	N/A
Former directorships (last 3 years)	N/A
Special responsibilities	Chair of Nomination and Remuneration Committee.
Interests in shares	1,456,864 fully paid ordinary shares

Name	Mr Ilario Thomas Faenza (resigned 20 May 2025)
Title	Independent Non-Executive Chair
Age	54
Experience and expertise	M&A, PE & investment banking specialist with over 30 years experience in a range of high growth industries. Ilario has successfully started multiple companies and provided advisory, specialist M&A, due diligence, structuring and fund raising assistance to numerous businesses. Ilario has raised > \$100M over the past 15 years for high growth companies and actively assists management with execution of strategy, commercial negotiations, IPO's and exit strategies.
Other current directorships	Harvest Technology Group Ltd
Former directorships (last 3 years)	N/A
Special responsibilities	Member of Audit & Risk Committee and Nomination and Remuneration Committee.
Interests in shares	2,956,605 fully paid ordinary shares

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Company secretary

George Lazarou has held the position of Company secretary from 27 January 2021. He is a qualified Chartered Accountant with over 30 years' experience, including five years as a partner of a

mid-tier accounting firm, specialising in the areas of advisory and corporate services. Mr Lazarou has extensive skills in the areas of corporate services, due diligence, independent expert reports, mergers & acquisitions and valuations.

Mr Lazarou has been Chair, Non-Executive Director and Company Secretary of a number of ASX listed companies since 2006.

Meetings of directors

The number of meetings of the company's Board of Directors ('the Board') and of each Board committee held during the year ended 30 June 2025, and the number of meetings attended by each director were:

	Full Board		Nomination and Remuneration Committee		Audit and Risk Committee	
	Held	Attended	Held	Attended	Held	Attended
Mr Geoffrey Sam OAM ¹	3	3	1	1	1	1
Mr Blair William Brabin Vega Norfolk ²	7	7	-	-	1	1
Ms Dominique Gayle Fisher AM ³	7	7	1	1	2	2
Mr Ilario Thomas Faenza ⁴	6	5	1	1	2	1
Dr Jaroslav Haman Boublik ⁵	-	-	-	-	1	1

Held: represents the number of meetings held during the time the director held office or was a member of the relevant committee.

- Appointed as a Director on 21 November 2024 and appointed to the Audit & Risk Committee and assumed the role of Chair on 17 February 2025 and appointed to the Nomination & Remuneration Committee on 28 February 2025
- Resigned from the Audit & Risk Committee on 17 February 2025
- Chair of the Nomination & Remuneration Committee and resigned as Chair of the Audit & Risk Committee on 17 February 2025
- Resigned as a Director on 20 May 2025
- Resigned from the Audit & Risk Committee on 17 February 2025 and Nomination & Remuneration Committee on 28 February 2025

Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the consolidated entity, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all directors.

The remuneration report is set out under the following main headings:

- Principles used to determine the nature and amount of remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional information
- Additional disclosures relating to key management personnel

Principles used to determine the nature and amount of remuneration

The objective of the consolidated entity's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:

- competitiveness and reasonableness
- acceptability to shareholders
- performance linkage / alignment of executive compensation
- transparency

The Nomination and Remuneration Committee is responsible for determining and reviewing remuneration arrangements for its directors and executives. The performance of the consolidated entity depends on the quality of its directors and executives. The remuneration philosophy is to attract, motivate and retain high performance and high quality personnel.

In consultation with external remuneration consultants (refer to the section 'Use of remuneration consultants' below), the Nomination and Remuneration Committee has structured an executive remuneration framework that is market competitive and complementary to the reward strategy of the consolidated entity.

The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that it should seek to enhance shareholders' interests by:

- having economic profit as a core component of plan design
- focusing on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value
- attracting and retaining high calibre executives

Additionally, the reward framework should seek to enhance executives' interests by:

- rewarding capability and experience
- reflecting competitive reward for contribution to growth in shareholder wealth
- providing a clear structure for earning rewards

In accordance with best practice corporate governance, the structure of non-executive director and executive director remuneration is separate.

Non-executive directors remuneration

Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors' fees and payments are reviewed annually by the Nomination and Remuneration Committee. The Nomination and Remuneration Committee may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market. The chair's fees are determined independently to the fees of other non-executive directors based on comparative roles in the external market. The chair is not present at any discussions relating to the determination of his own remuneration. Non-executive directors did not receive share options or other incentives.

ASX listing rules require the aggregate non-executive directors' remuneration to be determined periodically by a general meeting. The maximum aggregate amount of fees that can be paid to non-executive directors is subject to approval by shareholders at the Annual General Meeting (currently \$400,000).

Executive remuneration

The consolidated entity aims to reward executives based on their position and responsibility, with a level and mix of remuneration that has both fixed and variable components.

The executive remuneration and reward framework has four components:

- base pay and non-monetary benefits
- short-term performance incentives
- share-based payments
- other remuneration such as superannuation and long service leave

The combination of these comprises the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed annually by the Nomination and Remuneration Committee based on individual and business unit performance, the overall performance of the consolidated entity and comparable market remuneration.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle benefits) where it does not create any additional costs to the consolidated entity and provides additional value to the executive.

The short-term incentives ('STI') program aligns the targets of the business units with the performance hurdles of executives. STI payments are granted to executives based on specific annual targets and key performance indicators ('KPI's') being achieved. KPI's include sales revenue, profit contribution, customer satisfaction, leadership contribution and product management.

The long-term incentives ('LTI') include long service leave and share-based payments. Shares and/or cash are awarded to executives over a period of three years based on long-term incentive measures. This first LTI target for the managing director was met and exceeded for the 3 years ending FY24. A new \$1m LTI has been set for the managing director covering the 3-year period from FY25 to FY27 and is subject to meeting KPI targets set by the board, following engagement of Guerdon Associates, remuneration consultants. The Nomination and Remuneration Committee reviewed the long-term equity-linked performance incentives specifically for executives during the year ended 30 June 2025.

Consolidated entity performance and link to remuneration

Remuneration for specific individuals is directly linked to the performance of the consolidated entity. Cash bonus and incentive payments are linked to yearly sales revenue and gross margin, EBITDA and inventory targets being met for STI's with sales revenue and EBITDA targets being met over a 3-year period for LTI's. Any additional cash bonus and incentive payments are at the discretion of the Nomination and Remuneration Committee. Refer to the section 'Additional information' below for details of the earnings and total shareholders' return for the last five years.

The Nomination and Remuneration Committee is of the opinion that the continued improved results can be attributed in part to the adoption of performance based compensation and is satisfied that this improvement will continue to increase shareholder wealth if maintained over the coming years.

Use of remuneration consultants

During the financial year ended 30 June 2025, the consolidated entity, through the Nomination and Remuneration Committee, engaged Guerdon Associates, remuneration consultants, to put in place a LTI for management and a review of Board remuneration. Guerdon Associates was paid \$50,474 for these services.

An agreed set of protocols were put in place to ensure that the remuneration recommendations would be free from undue influence from key management personnel. These protocols include requiring that the consultant not communicate with affected key management personnel without a member of the Nomination and Remuneration Committee being present, and that the consultant not provide any information relating to the outcome of the engagement with the affected key management personnel. The Board is also required to make inquiries of the consultant's processes at the conclusion of the engagement to ensure that they are satisfied that any recommendations made have been free from undue influence. The Board is satisfied that these protocols were followed and as such there was no undue influence.

Voting and comments made at the company's 19 November 2024 Annual General Meeting ('AGM')

At the 19 November 2024 AGM, 95.41% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2024. The company did not receive any specific feedback at the AGM regarding its remuneration practices.

Details of remuneration*Amounts of remuneration*

Details of the remuneration of key management personnel of the consolidated entity are set out in the following tables.

The key management personnel of the consolidated entity consisted of the following:

- Mr Geoffrey Sam OAM
– Independent Non-Executive Chair
(appointed 21 November 2024)
- Mr Blair William Brabin Vega Norfolk
– Managing Director
- Ms Dominique Gayle Fisher AM
– Independent Non-Executive Director
- Mr Douglas Chee Yong Loh
– Chief Financial Officer
- Mr Ilario Thomas Faenza
– Independent Non-executive Chair
(resigned 20 May 2025)

30 June 2025	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	Total
	Cash salary and fees	Cash bonus	Non-monetary	Super-annuation	Cash bonus	Equity-settled	
Non-Executive Directors							
Mr Geoffrey Sam OAM *	\$ 51,695	-	-	\$ 3,493	-	-	\$ 55,188
Ms Dominique Gayle Fisher AM	\$ 81,667	-	-	\$ 9,392	-	-	\$ 91,059
Mr Ilario Thomas Faenza **	\$ 119,725	-	-	-	-	-	\$ 119,725
Executive Directors							
Mr Blair William Brabin Vega Norfolk	\$ 450,000	\$ 100,000	-	\$ 30,000	-	-	\$ 580,000
Other Key Management Personnel							
Mr Douglas Chee Yong Loh	\$ 300,000	\$ 100,000	-	\$ 30,000	-	-	\$ 430,000
	\$ 1,003,087	\$ 200,000	-	\$ 72,885	-	-	\$ 1,275,972

* Including directors fees (ex GST) paid to Rose Terrace Investments Pty Ltd, a company associated with Mr Geoffrey Sam

** Including directors fees (ex GST) paid to Faenza Consulting Pty Ltd, a company associated with Mr Ilario Faenza

30 June 2024	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	Total
	Cash salary and fees	Cash bonus	Non-monetary	Super-annuation	Cash bonus	Equity-settled	
Non-Executive Directors:							
Ms Dominique Gayle Fisher AM	\$ 85,000	-	-	\$ 9,350	-	\$ 8,643	\$ 102,993
Mr Ilario Thomas Faenza	\$ 108,780	-	-	-	-	\$ 12,965	\$ 121,745
Executive Directors:							
Mr Blair William Brabin Vega Norfolk	\$ 350,000	\$ 150,000	-	\$ 27,424	\$ 1,000,000	\$ 34,573	\$ 1,561,997
Other Key Management Personnel:							
Mr Douglas Chee Yong Loh	\$ 275,000	\$ 100,000	-	\$ 27,424	-	\$ 17,287	\$ 419,711
	\$ 818,780	\$ 250,000	-	\$ 64,198	\$ 1,000,000	\$ 73,468	\$ 2,206,446

The proportion of remuneration linked to performance and the fixed proportion are as follows:

	Fixed remuneration		At risk — STI		At risk — LTI	
	30 June 2025	30 June 2024	30 June 2025	30 June 2024	30 June 2025	30 June 2024
Non-Executive Directors:						
Mr Geoffrey Sam OAM	100%	-	-	-	-	-
Ms Dominique Gayle Fisher AM	100%	92%	-	-	-	8%
Mr Ilario Thomas Faenza	100%	89%	-	-	-	11%
Executive Directors:						
Mr Blair William Brabin Vega Norfolk	83%	24%	17%	10%	-	66%
Other Key Management Personnel:						
Mr Douglas Chee Yong Loh	77%	72%	23%	24%	-	4%

Service agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name	Mr Blair William Brabin Vega Norfolk
Title	Managing Director
Agreement commenced	Upon listing
Term of agreement	No fixed term
Details	\$450,000 per annum plus super (as from 1 July 2024) Short-term and Long term-incentive payments in the event that certain milestones are achieved. The agreement is subject to a mutual six month notice period but may be terminated by the Company in the event of serious misconduct.

Name	Mr Douglas Chee Yong Loh
Title	Chief Financial Officer
Agreement commenced	Upon listing
Term of agreement	No fixed term
Details	\$300,000 per annum plus super (as from 1 July 2024) Short-term and Long term-incentive payments in the event that certain milestones are achieved. The agreement is subject to a mutual six month notice period but may be terminated by the Company in the event of serious misconduct.

Key management personnel have no entitlement to termination payments in the event of removal for misconduct.

Share-based compensation*Issue of Performance Rights*

There were no performance rights issued during the year to directors and other key management personnel as part of compensation during the year ended 30 June 2025.

Options

There were no options over ordinary shares issued to directors and other key management personnel as part of compensation that were outstanding as at 30 June 2025.

There were no options over ordinary shares granted to or vested by directors and other key management personnel as part of compensation during the year ended 30 June 2025.

Loan Funded Share Plan

On 27 June 2025, the company issued 812,355 ordinary shares, with 95,460 shares vesting on 30 July 2025 and 716,895 shares vesting on 30 July 2026, under its (LFSP) Loan Funded Share Plan, with a 10-year non-recourse loan term. The equity value of these shares are recognised and credited to the Share Capital account as and when the loans are repaid.

(*) Valuation of LFSP are determined by using industry standard Black-Scholes-Merton (BSM) model taking into account the terms and conditions upon which instruments are issued.

Employee Incentive Scheme

A total of 1,042,484 ordinary shares were issued to personnel, including those issued under the aforementioned LFSP, as part of the Company's Employee Incentive Scheme during the year ended 30 June 2025.

Additional information

The earnings of the consolidated entity for the five years to 30 June 2025 are summarised below:

	2025	2024	2023	2022	2021
Sales revenue	\$ 18,417,188	\$ 13,008,897	\$ 7,235,611	\$ 4,122,425	\$ 2,318,402
Net profit/(losses) after tax	\$ 214,656	\$ (1,670,202)	\$ (3,078,527)	\$ (4,470,580)	\$ (5,381,116)
Share price at beginning of year	\$0.58	\$0.072	\$0.075	\$0.20	-
Share price at the end of the year	\$0.455	\$0.58	\$0.072	\$0.075	-

Additional disclosures relating to key management personnel*Shareholding*

The number of shares in the company held during the financial year by each director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below:

Ordinary shares	Balance at the start of the year	Received as part of remuneration	Additions	Disposals/other	Balance at the end of the year
Mr Ilario Thomas Faenza (resigned 20 May 2025)	2,939,605	-	17,000	-	2,956,605 ¹
Mr Blair William Brabin Vega Norfolk	18,387,272	-	100,000	-	18,487,272
Ms Dominique Gayle Fisher AM	1,411,864	-	45,000	-	1,456,864
Mr Douglas Chee Yong Loh	14,190,025	-	-	-	14,190,025
Mr Geoffrey Sam OAM (appointed 21 November 2024)	4,159,512 ²	-	183,025	-	4,342,537
	41,088,278	-	345,025	-	41,433,303

1. Represents balance as at date of resignation, being 20 May 2025

2. Represents balance as at date of appointment, being 21 November 2024

This concludes the remuneration report, which has been audited.

Shares under option

Unissued ordinary shares of Biome Australia Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
31 March 2023	31 March 2026	\$0.12	625,000
31 March 2023	31 March 2026	\$0.20	2,250,000
8 March 2024	31 March 2026	\$0.50	2,500,000
			5,375,000

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the company or of any other body corporate.

Shares issued on the exercise of options

The following ordinary shares of Biome Australia Limited were issued during the year ended 30 June 2025 and up to the date of this report on the exercise of options granted:

Date options exercised	Exercise price	Number of shares issued
5 July 2024	\$0.12	300,000
10 September 2024	\$0.40	2,131,404
10 September 2024	\$0.20	50,000
10 September 2024	\$0.12	1,550,000
20 December 2024	\$0.20	75,000
4 March 2025	\$0.20	125,000
		4,231,404

Indemnity and insurance of officers

The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the company paid a premium of \$24,337 in respect of a contract to insure the directors and executives of the company against a liability to the extent permitted by the Corporations Act 2001. The sum insured for Directors' and Officers' Liability Insurance is \$1 million.

Indemnity and insurance of auditor

The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

Proceedings on behalf of the company

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.

Non-audit services

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 29 to the financial statements.

The directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.

On behalf of the directors



Mr Geoffrey Sam OAM
Chair

29 September 2025

The directors are of the opinion that the services as disclosed in note 29 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the company, acting as advocate for the company or jointly sharing economic risks and rewards.

Officers of the company who are former partners of MVAB Assurance

There are no officers of the company who are former partners of MVAB Assurance.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Auditor

MVAB Assurance continues in office in accordance with section 327 of the Corporations Act 2001.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.



**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF BIOME AUSTRALIA LIMITED
ABN: 51 627 364 014**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2025 there have been:

- (i) No contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and
- (ii) No contraventions of any applicable code of professional conduct in relation to the audit.

MVAB Assurance

MVAB ASSURANCE
Chartered Accountants



SAM CLARINGBOLD
Partner

Signed at Melbourne this 29th September 2025

**Statement of profit or loss and other comprehensive income
for the year ended 30 June 2025**

	Consolidated		
	Note	30 June 2025	30 June 2024
Revenue			
Sales revenue	5	\$ 18,417,188	\$ 13,008,897
Cost of goods sold		(\$7,160,900)	(\$5,097,676)
Gross profit		\$ 11,256,288	\$ 7,911,221
Other income	6	\$ 482,396	\$ 415,749
Expenses			
Sales and marketing expenses	7	(\$7,537,917)	(\$5,851,611)
Corporate and administrative expenses	7	(\$3,322,177)	(\$3,658,447)
Distribution and occupancy expenses		(\$117,738)	(\$72,846)
Depreciation, amortisation and impairments	7	(\$241,970)	(\$241,560)
Other expenses		(\$36,847)	(\$21,160)
Finance costs	7	(\$267,379)	(\$151,548)
Profit/(loss) before income tax expense		\$ 214,656	(\$1,670,202)
Income tax expense	8	-	-
Profit/(loss) after income tax expense for the year attributable to the owners of Biome Australia Limited	25	\$ 214,656	(\$1,670,202)
Other comprehensive income for the year, net of tax	8	-	-
Total comprehensive income for the year attributable to the owners of Biome Australia Limited		\$ 214,656	(\$1,670,202)
Basic earnings per share	34	\$ 0.10	(\$0.80)
Diluted earnings per share	34	\$ 0.10	(\$0.80)

Statement of financial position as at 30 June 2025

	Note	Consolidated	
		30 June 2025	30 June 2024
Assets			
Current assets			
Cash and cash equivalents	9	\$ 2,746,416	\$ 2,868,526
Trade and other receivables	10	\$ 4,327,593	\$ 2,870,022
Inventories	11	\$ 4,111,914	\$ 1,888,577
Other	12	\$ 255,306	\$ 81,361
Total current assets		\$ 11,441,229	\$ 7,708,486
Non-current assets			
Property, plant and equipment	13	\$ 224,585	\$ 331,380
Right-of-use assets	14	\$ 138,887	\$ 236,925
Intangibles	15	\$ 163,239	-
Total non-current assets		\$ 526,711	\$ 568,305
Total assets		\$ 11,967,940	\$ 8,276,791
Liabilities			
Current liabilities			
Trade and other payables	16	\$ 3,600,102	\$ 2,492,301
Borrowings	17	\$ 2,905,413	\$ 1,020,597
Lease liabilities	18	\$ 116,833	\$ 107,952
Employee benefits	19	\$ 557,676	\$ 1,522,673
Total current liabilities		\$ 7,180,024	\$ 5,143,523
Non-current liabilities			
Lease liabilities	20	\$ 50,979	\$ 167,812
Employee benefits	21	\$ 61,570	\$ 52,570
Other liabilities	22	-	\$ 9,358
Total non-current liabilities		\$ 112,549	\$ 229,740
Total liabilities		\$ 7,292,573	\$ 5,373,263
Net assets		\$ 4,675,367	\$ 2,903,528
Equity			
Issued capital	23	\$ 23,323,346	\$ 21,727,165
Reserves	24	\$ 406,618	\$ 444,212
Accumulated losses	25	\$ (19,054,597)	\$ (19,267,849)
Total equity		\$ 4,675,367	\$ 2,903,528

**Statement of changes in equity
for the year ended 30 June 2025**

Consolidated	Issued capital	Option reserves	Accumulated losses	Total equity
Balance at 1 July 2023	\$ 20,764,055	\$ 421,257	\$ (17,599,047)	\$ 3,586,265
Loss after income tax expense for the year	-	-	\$ (1,670,202)	\$ (1,670,202)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	\$ (1,670,202)	\$ (1,670,202)
Transactions with owners in their capacity as owners:				
Share-based payments (note 35)	\$ 122,532	\$ 92,987	-	\$ 215,519
Issue of options	-	\$ 128,125	-	\$ 128,125
Exercise of options	\$ 840,578	\$ (198,157)	-	\$ 642,421
Consolidation — currency adjustment	-	-	\$ 1,400	\$ 1,400
Balance at 30 June 2024	\$ 21,727,165	\$ 444,212	\$ (19,267,849)	\$ 2,903,528

Consolidated	Issued capital	Option reserves	Accumulated losses	Total equity
Balance at 1 July 2024	\$ 21,727,165	\$ 444,212	\$ (19,267,849)	\$ 2,903,528
Profit after income tax expense for the year	-	-	\$ 214,656	\$ 214,656
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	\$ 214,656	\$ 214,656
Transactions with owners in their capacity as owners:				
Share-based payments (note 35)	\$ 471,619	\$ (37,594)	\$ -	\$ 434,025
Issue of options	-	-	-	-
Exercise of options	\$ 1,124,562	-	-	\$ 1,124,562
Consolidation — currency adjustment	-	-	\$ (1,404)	\$ (1,404)
Balance at 30 June 2025	\$ 23,323,346	\$ 406,618	\$ (19,054,597)	\$ 4,675,367

Statement of cash flows
for the year ended 30 June 2025

	Consolidated		
	Note	30 June 2025	30 June 2024
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		\$ 16,833,117	\$ 12,790,769
Payments to suppliers (inclusive of GST)		\$(19,994,220)	\$(13,354,625)
R&D tax refund		\$ 337,167	\$ 314,937
Export Market Development Grant and State Government grants		\$ 73,084	\$ 36,600
Interest paid on lease liabilities		\$(139,952)	\$(15,699)
Interest received		\$ 71,145	\$ 64,212
Net cash used in operating activities	33	\$(2,819,659)	\$(163,806)
Cash flows from investing activities			
Payments for property, plant and equipment	13	\$(37,138)	\$(21,607)
Payments for intellectual property		\$(163,239)	-
Net cash used in investing activities		\$(200,377)	\$(21,607)
Cash flows from financing activities			
Proceeds from exercise of options	23	\$ 1,124,562	\$ 642,421
Proceeds from repayment of (Employee) Loan Funded Share Plan		\$ 27,500	\$ -
Repayments for lease liabilities		\$(108,952)	\$(99,585)
Proceeds from borrowings		\$ 2,904,816	\$ 520,597
Repayment of borrowings		\$(1,050,000)	\$(270,258)
Net cash from financing activities		\$ 2,897,96	\$ 793,175
Net increase/(decrease) in cash and cash equivalents		\$(122,110)	\$ 607,762
Cash and cash equivalents at the beginning of the financial year		\$ 2,868,526	\$ 2,260,764
Cash and cash equivalents at the end of the financial year	9	\$ 2,746,416	\$ 2,868,526

Note 1. General information

The financial statements cover Biome Australia Limited as a consolidated entity consisting of Biome Australia Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Biome Australia Limited's functional and presentation currency.

Biome Australia Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office

192-194 Johnston Street
Collingwood Victoria 3066

Principal place of business

192-194 Johnston Street
Collingwood Victoria 3066

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 29 September 2025. The directors have the power to amend and reissue the financial statements.

Note 2. Material accounting policy information

The accounting policies that are material to the consolidated entity are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International

Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial instruments.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

Parent entity information

In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 31.

Revenue recognition

The consolidated entity recognises revenue as follows:

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject

to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Sale of goods

Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery.

Rendering of services

Revenue from a contract to provide services is recognised over time as the services are rendered based on either a fixed price or an hourly rate.

Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period

ended 30 June 2025. The consolidated entity has not yet assessed the impact of these new or amended Accounting Standards and Interpretations.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Provision for impairment of inventories

The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Estimation of useful lives of assets

The consolidated entity determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Recovery of deferred tax assets

Deferred tax assets are recognised for deductible temporary differences only if the consolidated entity considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Note 4. Operating segments*Identification of reportable operating segments*

The company is organised into one operating segment: researching, developing, manufacturing and distributing innovative evidence-based products linking the gut and human health. This operating segment is based

on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Accounting policy for operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

Note 5. Sales revenue

	Consolidated	
	30 June 2025	30 June 2024
Sales — Domestic	\$ 16,930,499	\$ 12,114,477
Sales — International	\$ 1,486,689	\$ 894,420
	\$ 18,417,188	\$ 13,008,897

Note 6. Other income

	Consolidated	
	30 June 2025	30 June 2024
Other income (incl. EMDG — Export Market Development Grant)	\$ 73,084	\$ 36,600
Interest income	\$ 72,145	\$ 64,212
R&D tax refund	\$ 337,167	\$ 314,937
	\$ 482,396	\$ 415,749

Note 7. Expenses

	Consolidated	
	30 June 2025	30 June 2024
Selling and marketing expenses		
Employee costs	\$ 3,099,949	\$ 2,449,669
Overseas contractors / consultants	\$ 699,241	\$ 397,436
Sales, marketing and research expenses	\$ 1,385,869	\$ 1,264,654
Warehousing, distribution and fulfilment	\$ 1,486,524	\$ 1,039,570
Travel and entertainment expenses	\$ 769,873	\$ 580,848
Share based payments	\$ 96,461	\$ 119,434
	\$ 7,537,917	\$ 5,851,611

	Consolidated	
	30 June 2025	30 June 2024
Corporate and administrative expenses		
Employee costs	\$ 2,114,455	\$ 1,653,574
CEO – Long term incentive	–	\$ 1,000,000
Consulting fees	\$ 92,295	\$ 65,427
Accounting fees	\$ 82,204	\$ 125,048
IT expenses	\$ 213,836	\$ 156,307
Insurance	\$ 158,301	\$ 109,271
Secretarial fees	\$ 92,168	\$ 78,264
Legal fees	\$ 146,028	\$ 119,039
Other administrative expenses	\$ 112,825	\$ 127,748
Share based payments*	\$ 310,065	\$ 223,769
	\$ 3,322,177	\$ 3,658,447

*Includes \$110,000 (FY24 \$128,128) for share based payments to non-related third party service providers

	Consolidated	
	30 June 2025	30 June 2024
Depreciation, amortisation and impairments		
Depreciation expense	\$ 143,932	\$ 143,522
Amortisation expense on right-of-use asset	\$ 98,038	\$ 98,038
	\$ 241,970	\$ 241,560

	Consolidated	
	30 June 2025	30 June 2024
Finance costs		
Interest expense	\$ 129,253	\$ 144,787
Interest expense on leases/right-of-use assets	\$ 10,789	\$ 15,699
Bank charges	\$ 52,494	\$ 1,455
Merchant fees	\$ 4,136	\$ 3,383
Foreign exchange losses/(gains)	\$ 70,707	\$ (13,776)
	\$ 267,379	\$ 151,548

Note 8. Income tax expense

	Consolidated	
	30 June 2025	30 June 2024
Numerical reconciliation of income tax expense and tax at the statutory rate		
Profit/(loss) before income tax expense	\$ 214,656	(\$1,670,202)
Tax at the statutory tax rate of 25%	\$ 53,664	(\$417,551)
Tax effect amounts which are not deductible/ (taxable) in calculating taxable income:		
Effects of different tax rates for foreign subsidiary	\$ 56,507	\$ 28,891
R&D refund	(\$84,292)	(\$78,743)
R&D expenses	\$ 193,774	\$ 180,998
Share-based payments	\$ 101,632	\$ 32,031
Timing differences not recognised	(\$55,290)	\$ 841,041
	\$ 265,995	\$ 586,667
Prior year tax losses utilised	(\$265,995)	-
Current year tax losses not recognised	-	(\$586,667)
Income tax expense	-	-

	Consolidated	
	30 June 2025	30 June 2024
Tax losses not recognised		
Unused tax losses for which no deferred tax asset has been recognised	\$10,501,653	\$10,767,648
Potential tax benefit @ 25%	\$2,625,413	\$2,691,912

The above potential tax benefit for tax losses has not been recognised in the statement of financial position. These tax losses can only be utilised in the future if the continuity of ownership test is passed, or failing that, the same business test is passed and the Group generates sufficient taxable earnings.

Note 9. Current assets — cash and cash equivalents

	Consolidated	
	30 June 2025	30 June 2024
Cash at bank	\$2,746,416	\$2,868,526

Accounting policy for cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Note 10. Current assets — trade and other receivables

	Consolidated	
	30 June 2025	30 June 2024
Trade receivables	\$ 4,327,593	\$ 2,870,022

Accounting policy for trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Note 11. Current assets — inventories

	Consolidated	
	30 June 2025	30 June 2024
Raw materials — at cost	\$ 490,958	\$ 382,388
Finished goods — at cost	\$ 3,666,706	\$ 1,812,308
Provision for slow moving and obsolete stock	\$ (45,750)	\$ (306,119)
	\$ 4,111,914	\$ 1,888,577

Accounting policy for inventories

Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value on a 'first in first out' basis. Cost comprises of direct materials and delivery costs, direct labour, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity, and, where applicable, transfers from cash flow hedging reserves in equity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable.

Stock in transit is stated at the lower of cost and net realisable value. Cost comprises of purchase and delivery costs, net of rebates and discounts received or receivable.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Note 12. Current assets — other

	Consolidated	
	30 June 2025	30 June 2024
Bank guarantee	\$ 30,250	\$ 30,250
Prepayments	\$ 168,319	-
Other	\$ 56,737	\$ 51,111
	\$ 255,306	\$ 81,361

Note 13. Non-current assets – property, plant and equipment

	Consolidated	
	30 June 2025	30 June 2024
Property, plant and equipment – at cost	\$ 590,618	\$ 637,019
Less: Accumulated depreciation	(\$366,033)	(\$305,639)
	\$ 224,585	\$ 331,380

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Office Equipment and Furniture, Fixtures and Fittings	Motor Vehicles	Leasehold Improvement	Total
Balance at 1 July 2023	\$ 52,273	\$ 20,104	\$ 380,918	\$ 453,295
Additions	\$ 21,607	-	-	\$ 21,607
Depreciation expense	\$(11,930)	\$(20,104)	\$(111,488)	\$(143,522)
Balance at 30 June 2024	\$ 61,950	-	\$ 269,430	\$ 331,380
Additions	\$ 37,138	-	-	\$ 37,138
Disposals	-	-	-	-
Depreciation expense	\$(18,720)	-	\$(125,213)	\$(143,933)
Balance at 30 June 2025	\$ 80,368	-	\$ 144,217	\$ 224,585

Accounting policy for property, plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

Leasehold improvements	3–10 years
Motor vehicles	4 years
Plant and equipment	3–7 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

Leasehold improvements are depreciated over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the consolidated entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

Note 14. Non-current assets – right-of-use assets

	Consolidated	
	30 June 2025	30 June 2024
Right-of-use assets	\$ 490,189	\$ 490,189
Amortisation expense	(\$351,302)	(\$253,264)
	\$ 138,887	\$ 236,925

Accounting policy for right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the consolidated entity expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

Note 15. Non-current assets – intangibles

	Consolidated	
	30 June 2025	30 June 2024
Intellectual property – at cost	\$ 133,105	-
Other intangible assets – at cost	\$ 30,134	-
	\$ 163,239	-

Accounting policy for intangible assets

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

Note 16. Current liabilities – trade and other payables

	Consolidated	
	30 June 2025	30 June 2024
Trade and other payables	\$ 3,600,102	\$ 2,492,301

Refer to note 27 for further information on financial instruments.

Accounting policy for trade and other payables

These amounts represent liabilities for goods and services provided to the consolidated entity prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 61 days of recognition.

Note 17. Current liabilities — borrowings

	Consolidated	
	30 June 2025	30 June 2024
Loan from TP24 - Debtor Financing Facility	-	\$1,000,000
Loan — other	-	\$20,597
Loan — NAB Trade Finance	\$1,300,000	-
Loan — NAB Invoice Finance	\$1,605,413	-
	\$2,905,413	\$1,020,597

Refer to note 27 for further information on financial instruments.

Accounting policy for borrowings

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Note 18. Current liabilities — lease liabilities

	Consolidated	
	30 June 2025	30 June 2024
Lease liability	\$116,833	\$107,952

Lease liabilities

The maturity analysis of lease liabilities based on contractual undiscounted cash flows is shown in the table below:

	1 year	1–5 years	5 years	Total undiscounted lease liabilities	Lease liabilities included in this Statement of Financial Position
Lease liabilities 2025	\$122,303	\$51,586	-	\$173,889	\$167,812
Lease liabilities 2024	\$118,741	\$173,889	-	\$292,630	\$275,765
	\$241,044	\$225,475	-	\$466,519	\$443,577

The amounts recognised in the statement of profit or loss and other comprehensive income relating to interest expense on lease liabilities and short term leases or leases of low value assets are shown below:

	2025	2024
Interest expense on lease liabilities	\$10,789	\$15,699
Depreciation expense	\$118,562	\$98,038
	\$129,351	\$113,737

Note 19. Current liabilities — employee benefits

	Consolidated	
	30 June 2025	30 June 2024
Annual leave	\$ 250,485	\$ 244,274
Long service leave	\$ 107,191	\$ 55,399
Employee benefits	\$ 200,000	\$ 1,223,000
	\$ 557,676	\$ 1,522,673

*Accounting policy for employee benefits**Short-term employee benefits*

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Note 20. Non-current liabilities — lease liabilities

	Consolidated	
	30 June 2025	30 June 2024
Lease liability	\$ 50,979	\$ 167,812

Accounting policy for lease liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the consolidated entity's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

Note 21. Non-current liabilities — employee benefits

	Consolidated	
	30 June 2025	30 June 2024
Long service leave	\$ 61,570	\$ 52,570

Accounting policy for other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Note 22. Non-current liabilities – other liabilities

	Consolidated	
	30 June 2025	30 June 2024
Other – Attvest Finance Pty Ltd	-	\$9,358

Note 23. Equity – issued capital

	Consolidated			
	30 June 2025	30 June 2024	30 June 2025	30 June 2024
	Shares	Shares	\$	\$
Ordinary shares – fully paid	220,609,231	215,090,901	\$23,323,346	\$21,727,165

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2023	201,812,546		\$20,764,055
Shares issued under Employee Incentive Scheme	5 October 2023	560,393	\$0.13	\$75,007
Shares issued under Employee Incentive Scheme pursuant to the Loan Funded Share Plan (LFSP)	1 December 2023	9,612,708	\$0.12	-
Exercise of options	15 February 2024	25,000	\$0.12	\$3,000
Shares issued under Employee Incentive Scheme pursuant to the Loan Funded Share Plan (LFSP)	10 April 2024	817,434	\$0.33	-
Shares issued under Employee Incentive Scheme	14 June 2024	131,416	\$0.36	\$47,525
Exercise of options	21 June 2024	2,131,404	\$0.30	\$639,421
Transfer from Share options reserve	21 June 2024	-	-	\$198,157
Balance	30 June 2024	215,090,901		\$21,727,165
Exercise of options	5 July 2024	300,000	\$0.12	\$36,000
Exercise of options	10 September 2024	2,131,404	\$0.40	\$852,562
Exercise of options	10 September 2024	50,000	\$0.20	\$10,000
Exercise of options	10 September 2024	1,550,000	\$0.12	\$186,000
Exercise of options	20 December 2024	75,000	\$0.20	\$15,000
Exercise of options	4 March 2025	125,000	\$0.20	\$25,000
Shares issued under Employee Incentive Scheme	27 June 2025	1,042,484	\$0.42	\$436,801
Shares issued for advisory services	27 June 2025	244,442	\$0.45	\$109,999
Transfer from Share options reserve		-	-	(\$75,181)
Balance	30 June 2025	220,609,231		\$23,323,346

Employee incentive share issues:

On 27 June 2025 the Company issued 1,042,484 ordinary shares under its Employee Incentive Scheme, as follows:

(a) 812,355 ordinary shares were issued under its Loan Funded Share Plan (LFSP) with 95,460 shares vesting on 30 July 2025 and 716,895 shares vesting on 30 July 2026, all with a 10-year non-recourse loan term. The equity value of these shares are recognised and credited to the Share Capital account as and when the loans are repaid; and

(b) 230,129 ordinary shares to staff members for achieving sales targets. These shares vest on issue.

(*) Valuation of LFSP are determined by using industry standard Black-Scholes-Merton (BSM) model taking into account the terms and conditions upon which instruments are issued.

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Capital risk management

The consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going

concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current company's share price at the time of the investment. The consolidated entity is not actively pursuing additional investments in the short term as it continues to integrate and grow its existing businesses in order to maximise synergies.

The consolidated entity is subject to certain financing arrangements covenants and meeting these is given priority in all capital risk management decisions. There have been no events of default on the financing arrangements during the financial year.

Accounting policy for issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Note 24. Equity – reserves

	Consolidated	
	30 June 2025	30 June 2024
Share option and performance rights reserves	\$ 406,618	\$ 444,212

Note 25. Equity — accumulated losses

	Consolidated	
	30 June 2025	30 June 2024
Accumulated losses at the beginning of the financial year	(\$19,267,849)	(\$17,599,047)
Profit/(loss) after income tax expense for the year	\$ 214,656	(\$1,670,202)
Consolidation — currency adjustment	(\$1,404)	\$ 1,400
Accumulated losses at the end of the financial year	(\$19,054,597)	(\$19,267,849)

Note 26. Equity — dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 27. Financial instruments*Financial risk management objectives*

The consolidated entity's principal financial instruments comprise cash, short term deposits and equity investments. The main purpose of the cash and term deposit is to earn the maximum amount of interest at a low risk to the consolidated entity. The consolidated entity also has other financial instruments such as trade debtors and creditors which arise directly from its operations. For the period under review, it has been the consolidated entity's policy not to trade in financial instruments.

The directors' overall risk management strategy seeks to assist the consolidated entity in meeting its financial targets, whilst minimising potential adverse effects on financial performance.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the consolidated entity and appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the consolidated entity's operating units. Finance reports to the Board on a monthly basis.

Market risk*Foreign currency risk*

The consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and

financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

Price risk

The consolidated entity is not exposed to any significant price risk.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature. At 30 June 2025, the consolidated entity's cash/cash equivalents (note 9) are variable interest rate instruments earning approximately 2.75% p.a. at call interest.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The consolidated entity has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults. The consolidated entity only transacts with entities that are rated the equivalent of investment grade and above. The consolidated entity's exposure and the credit ratings of its counterparties are continuously monitored. Credit exposure is controlled by counterparty limits that are reviewed and approved by the Board annually. The consolidated entity does not have any borrowings and therefore does not have any associated credit risk.

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year.

Liquidity risk

Vigilant liquidity risk management requires the consolidated entity to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The consolidated entity manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Note 28. Fair value measurement*Accounting policy for fair value measurement*

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure

purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Note 29. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by MVAB Assurance, the auditor of the company:

	Consolidated	
	30 June 2025	30 June 2024
Audit services — Audit or review of the financial statements		
MVAB Assurance, Australia	\$ 48,000	\$ 37,000
The M Group Partnership, United Kingdom	\$ 12,574	\$ 8,512
Audit services	\$ 60,574	\$ 45,512
Non-audit services		
MVA Bennet Pty Ltd	\$ 18,650	\$ 16,090
The M Group Partnership, United Kingdom	\$ 17,394	\$ 7,006
Non-audit services	\$ 36,044	\$ 23,096

Note 30. Related party transactions*Parent entity*

Biome Australia Limited is the parent entity.

Note 31. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Parent	
	30 June 2025	30 June 2024
Loss after income tax	(\$1,027,845)	(\$447,010)
Total comprehensive income	(\$1,027,845)	(\$447,010)

Statement of financial position

	Parent	
	30 June 2025	30 June 2024
Total current assets	\$ 80,640	\$ 1,627,301
Total assets	\$ 18,077,658	\$ 17,554,922
Total current liabilities	\$ 106,432	\$ 114,438
Total liabilities	\$ 106,432	\$ 114,438
Equity		
Issued capital	\$ 23,323,157	\$ 21,726,975
Share option and performance rights reserves	\$ 406,618	\$ 444,213
Accumulated losses	(\$5,758,549)	(\$4,730,704)
Total equity	\$ 17,971,226	\$ 17,440,484

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The parent entity has entered into a Deed of Guarantee and Indemnity in relation to a \$5.0 million (2024: \$1.5 million) secured debt facility of its wholly owned subsidiary, Biome Australia Trading Pty Ltd with NAB Limited as at 30 June 2025.

Interest in subsidiaries

Subsidiaries	Principal place of business / Country of Incorporation	Percentage Owned 2025	Percentage Owned 2024
Biome Australia Trading Pty Ltd	Melbourne, Victoria, Australia	100%	100%
Biome Australia IP Pty Ltd	Melbourne, Victoria, Australia	100%	100%
Biome Australia Trading (UK) Limited	London, United Kingdom	100%	100%

Contingent liabilities

The Chief Financial Officer (CFO) is entitled to a long-term incentive (LTI) of \$250,000 that will vest and be payable based on the CFO remaining in his current role for a minimum set period during the 2026 financial year.

The parent entity has no other known contingent liabilities as at 30 June 2025 (2024: nil).

Capital commitments — Property, plant and equipment

The parent entity had no capital commitments as at 30 June 2025 (2024: Nil).

Material accounting policy information

The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Investments in associates are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Note 32. Events after the reporting period

No matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 33. Reconciliation of profit/(loss) after income tax to net cash used in operating activities

	Consolidated	
	30 June 2025	30 June 2024
Profit/(loss) after income tax expense for the year	\$ 214,656	(\$1,670,202)
Adjustments for:		
Depreciation and amortisation	\$ 241,970	\$ 241,560
Share-based payments	\$ 406,526	\$ 343,204
Interest on lease payments	\$ 10,789	\$ 15,699
Change in operating assets and liabilities:		
Increase in trade and other receivables	\$ (1,631,516)	\$ (1,462,437)
(Increase)/decrease in inventories	\$ (2,233,337)	\$ 1,132,737
Increase in prepayments	\$ (173,945)	\$ (37,345)
Increase in trade and other payables	\$ 1,301,195	\$ 250,774
(Decrease)/increase in employee benefits	\$ (955,997)	\$ 1,022,204
Net cash used in operating activities	\$ (2,819,659)	\$ (163,806)

Note 34. Earnings per share

	Consolidated	
	30 June 2025	30 June 2024
Profit/(loss) after income tax attributable to the owners of Biome Australia Limited	\$ 214,656	(\$1,670,202)
Weighted average number of ordinary shares used in calculating basic earnings per share	218,472,578	208,040,790
Weighted average number of ordinary shares used in calculating diluted earnings per share	218,472,578	208,040,790
Basic earnings per share	0.10¢	(0.80¢)
Diluted earnings per share	0.10¢	(0.80¢)

*Accounting policy for earnings per share**Basic earnings per share*

Basic earnings per share is calculated by dividing the profit attributable to the owners of Biome Australia Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Note 35. Share-based payments

Set out below are summaries of shares issued under the Company's Employee Incentive Plan:

30 June 2025				
Issue Date	Security Issued	Issue Price	No of Security Issued	Value of Security Issued
18/01/2023	Fully paid shares	\$0.07	1,902,689	\$137,564
05/10/2023	Fully paid shares	\$0.13	560,393	\$74,756
01/12/2023	Fully paid shares	\$0.12	9,612,708	\$1,160,254
10/04/2024	Fully paid shares	\$0.33	817,434	\$269,998
14/06/2024	Fully paid shares	\$0.36	131,416	\$47,525
27/06/2025	Fully paid shares	\$0.45	474,571	\$213,564
27/06/2025	Fully paid shares	\$0.42	812,355	\$340,377

Set out below are summaries of options granted for services rendered:

30 June 2025							
Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/forfeited/other	Balance at the end of the year
24/11/2021	24/11/2025	\$0.40	\$ 2,131,404	-	(\$2,131,404)	-	-
31/03/2023	31/03/2026	\$0.12	\$ 2,475,000	-	(\$1,850,000)	-	\$ 625,000
31/03/2023	31/03/2026	\$0.20	\$ 2,500,000	-	(\$250,000)	-	\$ 2,250,000
08/03/2024	31/03/2026	\$0.50	\$ 2,500,000	-	-	-	\$ 2,500,000
			\$ 9,606,404	-	(\$4,231,404)	-	\$ 5,375,000

Share options granted carry no rights to dividends and no voting rights. The options fully vested on issue. Valuation of the options has been undertaken using an industry standard pricing model. Refer below for further information.

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
31/03/2023	31/03/2026	\$0.07	\$0.12	30.98%	-	2.93%	\$12,560
31/03/2023	31/03/2026	\$0.07	\$0.20	30.98%	-	2.93%	\$1,900
08/03/2024	31/03/2026	\$0.39	\$0.50	34.45%	-	3.60%	\$128,125

Accounting policy for share-based payments

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or

loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

Note 36. Commitments and Contingencies

(a) *Capital expenditure commitments*
The group has no capital commitments as at 30 June 2025 (2024: \$nil).

(b) *Contingent liabilities*
The Chief Financial Officer (CFO) is entitled to a long-term incentive (LTI) of \$250,000 that will vest and be payable based on the CFO remaining in his current role for a minimum set period during the 2026 financial year.

Consolidated entity disclosure statement for the year ended 30 June 2025

Set out below is relevant information relating to entities that are consolidated in the consolidated financial statements at the end of the financial year as required by the Corporations Act 2001 (s.295(3A)(a)).

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest	Tax residency
Biome Australia Limited	Body corporate	Australia	100.00%	Australia*
Biome Australia Trading Pty Ltd	Body corporate	Australia	100.00%	Australia*
Biome Australia IP Pty Ltd	Body corporate	Australia	100.00%	Australia*
Biome Australia Trading (UK) Limited	Body corporate	United Kingdom	100.00%	United Kingdom

*Biome Australia Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime.

Biome Australia Limited
Directors' declaration
30 June 2025

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 2 to the financial statements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2025 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



Mr Geoffrey Sam OAM
Chair

29 September 2025

BIOME AUSTRALIA LIMITED
ABN: 51 627 364 014INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
BIOME AUSTRALIA LIMITED**Report on the audit of the financial report****Opinion**

We have audited the accompanying financial report, being a general purpose financial report of Biome Australia Limited (the Company) and Controlled entities (the Group), which comprises the consolidated statement of financial position as at 30 June 2025, the consolidated statement of profit or loss and comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the period then ended, notes comprising a summary of material accounting policies and other explanatory information, consolidated entity disclosure statement and the directors' declaration.

In our opinion, the financial report of Biome Australia Limited and Controlled entities is in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the Group's financial position as at 30 June 2025 and of its performance for the period ended on that date; and
- (b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Share Options and Equity Transactions (refer to note 23 and 24)

The Group issued shares and options to directors and senior management under a share-based compensation plan. These arrangements have differing terms and conditions that give rise to different accounting outcomes.

Share based payment arrangements require judgmental assumptions including volatility rate and expected life in determining the fair value of the arrangements and the expensing of that fair value over the estimated service period.

In recognising these transactions, the Group performed a valuation to calculate the accounting expense. Details of the share based payment arrangements offered to directors, executive management, third parties and shareholders, are disclosed in the Remuneration Report.

The audit of the share-based payment arrangements and the associated expense is a key audit matter due to the judgements required in determining fair value.

How our audit addressed the key audit matter

To evaluate the share transactions, we performed the following procedures, amongst others:

- In performing our procedures we assessed the terms of the share based payment arrangements issued during the period including review of documentation issued to shareholders.
- We assessed the methodology used by the Group in valuing the share options.
- We assessed the expense recorded on the statement of comprehensive income.
- We assessed whether the disclosure in note 23 and 24 in relation to the arrangements was adequate and whether it complied with Australian Accounting Standards.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2025 but does not include the financial report and our auditor's report thereon. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001; and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001,

and for such internal control as the directors determine is necessary to enable the preparation of:

- i. the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and

Melbourne

Level 5 North Tower
485 La Trobe Street
Melbourne, Vic 3000
T. +61 9642 8000

E. info@mvabennett.com.au

- ii. the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

Further description of our responsibilities for the audit of the financial report is located at The Auditing and Assurance Standards Board Website at <http://www.auasb.gov.au/Home.aspx>. This description forms part of our auditor's report.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 26 to 31 of the directors' report for the year ended 30 June 2025. In our opinion, the Remuneration Report of Biome Australia Limited and Controlled entities, for the year ended 30 June 2025, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.



MVAB Assurance
Chartered Accountants

Signed at Melbourne this 29th day of September 2025



SAM CLARINGBOLD
Partner

1. Corporate Governance Summary

1.1 Roles and Responsibilities of Board and Management

The Role of the Board and Delegations

The Board is accountable to shareholders for the activities and performance of Biome Australia Limited (Biome) by overseeing the creation of sustainable shareholder value within an appropriate risk framework and having regard for stakeholder interests and community expectations.

The Board is responsible for setting Biome's vision and strategy. Biome's vision is to become the number one trusted probiotic brand in all markets we operate. Biome also works to prevent disease, improve health outcomes and quality of life, and make our products accessible to all. This is a long-term vision, and the Board sets strategic priorities each year to work towards fulfilling this vision.

Directors are actively involved in setting, approving and regularly monitoring Biome's strategic priorities and holding management accountable for progress.

This process includes one annual Board strategy meeting offsite, regular Board reporting and meetings, and discussion and review with management. Similarly, the Board ensures that rigorous governance processes operate effectively to guide decision making across the business.

The Board's responsibilities are set out in the Board Charter, which is available at: <https://biomeaust.app.box.com/s/la4mrj1i2146ryz4s93c81l25elr6ltz>

The Board's role and responsibilities include:

- establishing, promoting and maintaining the strategic direction of Biome;
- approving business plans, budgets and financial policies;
- considering management recommendations on strategic business matters;
- establishing, promoting and maintaining proper processes and controls to maintain the integrity of accounting and financial records and reporting;
- fairly and responsibly rewarding executives, having regard to the performance of the executives, Biome's risk management framework and culture, the interests of shareholders, market conditions and Biome's overall performance;
- adopting and overseeing of implementation of corporate governance practices;

- overseeing the establishment, promotion and maintenance of effective risk management policies and processes;
- reviewing Board composition and performance;
- appointing, evaluating and remunerating the Chief Executive Officer (CEO) the Chief Financial Officer (CFO) and appointing the Company Secretary; and
- determining the CEO's delegated authority.

The Board has established committees to assist in carrying out its responsibilities and to consider certain issues and functions in detail.

The Board committees are discussed at section 1.3.

Management responsibility

The Board has delegated to the CEO the authority and powers necessary to implement the strategies approved by the Board and to manage the business affairs of Biome within the policies and delegation limits specified by the Board from time to time. The CEO may delegate authority to management but remains accountable for all authorities delegated to management.

1.2 Directors' Skills Matrix

The Board has determined that its current members have an appropriate collective mix of skills, experience and expertise to:

- exercise independent judgement;
- have a proper understanding of, and competence to deal with, current and emerging issues of the business;
- encourage enhanced Biome performance; and
- effectively review and challenge the performance of management.

The Board's competencies are assessed annually and the results of the most recent (July 2025) assessment are shown in the table below.

Areas of expertise/ leadership qualities	Average Self-Assessment Rating*
Risk & Compliance	4.67
Financial & Audit	4.67
Strategy	5
Policy Development	5
Technology	3.67
Executive Management	5
Industry Specific Skills	4
Leadership	5
Ethics and Integrity	5
Contribution	5
Negotiation	5
Crisis Management	5
Previous Board Experience	4.67

*Self-assessment rating from 1 to 5, with 1 being the lowest and 5 being the highest

Given the relatively small size of the Board at present the Board skills matrix shows some skill gaps. The Board believes these gaps are effectively covered by access to subject matter experts as the need arises to complement the skills of the existing non-executive and executive directors.

Board Committees

To assist it in undertaking its duties, the Board has established the following standing committees:

- Audit & Risk Committee; and
- Nomination & Remuneration Committee.

Each committee has its own charter, copies of which are available at: <https://biomeaust.app.box.com/s/n819bmaz3tjh969w0bhafp3apua3ui3p>

The charters specify the composition, responsibilities, duties, reporting obligations, meeting arrangements, authority and resources available to the committees and the provisions for review of the charter.

Details of Directors' membership of each committee and those eligible members' attendance at meetings throughout the period from 1 July 2024 to 30 June 2025 are set out below.

During the period, 7 meetings of directors were held. Attendances by each director during the period were as shown in the table below:

Directors	Directors' Meetings		Audit & Risk		Nomination & Remuneration	
	Eligible to Attend	Attended	Eligible to Attend	Attended	Eligible to Attend	Attended
Ilario Faenza ¹	6	5	2	1	1	1
Geoffrey Sam ²	3	3	1	1	1	1
Blair Vega Norfolk ³	7	7	1	1	-	-
Dominique Fisher ⁴	7	7	2	2	1	1
Jaroslav Boublik ⁵	-	-	1	1	-	-

1. Resigned as a Director on 20 May 2025

2. Appointed to the Audit & Risk Committee and assumed the role of Chair on 17 February 2025 and appointed to the Nomination & Remuneration Committee on 28 February 2025

3. Resigned from the Audit & Risk Committee on 17 February 2025

4. Chair of the Nomination & Remuneration Committee and resigned as Chair of the Audit & Risk Committee on 17 February 2025

5. Resigned from the Audit & Risk Committee on 17 February 2025 and Nomination & Remuneration Committee on 28 February 2025

Given the Board was reduced from 4 to 3 members on 20 May 2025, the Board have decided it would be more effective for the role of the standing committees to be undertaken by the Board, effective from 1 July 2025.

1.3 Risk Management Framework

Biome's Board is responsible, in conjunction with senior management, for the management of risks associated with the business and implementing structures and policies to adequately monitor and manage these risks. The Board's Audit & Risk Committee (ARC) assists in discharging its risk management responsibilities. In particular, this committee assist the Board in setting the appropriate risk appetite and for ensuring that there is an effective risk management framework that is able to manage, monitor and control the various risks to which the business is exposed.

On a day-to-day basis, the CEO, has the responsibility for monitoring the implementation of the risk framework, including the monitoring, reporting and analysis of the various risks faced by the business, and providing effective challenges to activities and decisions that may materially affect Biome's risk profile.

Biome has a robust risk management framework which supports its operating segments, and its risk appetite distinguishes risks from which Biome will seek to make an economic return from those which it seeks to minimise and which it does not consider will provide a return. The management of these risks is fundamental to Biome's business, customers and to building long-term shareholder value.

In addition to having a separate risk management function, Biome recognises that a requirement for an effective risk management framework is for there to be a strong risk culture throughout the organisation, where risk is everybody's business. The foundation of this risk culture is a set of values, the Biome values. All employees are assessed against the Biome values as part of the annual performance review process, and this outcome contributes to the overall performance rating and remuneration outcomes. In addition to this, Biome regularly assesses

its risk culture through external audits to ensure that the management of risk and day-to-day compliance remains entrenched within the way in which Biome operates. The Board is responsible for setting and monitoring the risk appetite for Biome when pursuing its strategic objectives. The Board's approach to, and appetite for risk provides that, subject to earning acceptable economic returns, it can retain exposure to credit risk, liquidity risk and market risk.

- Credit default risk — is the risk of loss in the value of an asset due to a counterparty failing to discharge its contractual obligations when they fall due;
- Liquidity risk — is the potential impact of Biome's short, medium and long-term funding and liquidity management requirements; and
- Market risk — is the risk that changes in the market prices such as foreign exchange rates, interest rates and equity prices will affect Biome's income or value of its holdings of financial instruments.

Biome seeks to minimise or hedge the risks for which it does not consider an appropriate return can be generated.

These risks include:

- Foreign exchange risk — is the risk of a change in asset values as a result of movements in foreign exchange rates;
- Inflation risk — is the risk of a change in asset values and Biome's earnings as a result of movements in inflation both in Australia and jurisdictions in which Biome owns assets;
- Operational risk — is the risk of loss resulting from inadequate or failed internal processes, people and systems or from external events; and
- Regulatory and compliance risk — is the risk of legal or regulatory sanctions or loss as a result of Biome's failure to comply with laws, regulations or regulatory policy applying to its business.

Shareholder Information

The shareholder information set out below was applicable as at 28 September 2025.

Distribution of equitable securities

Analysis of number of equitable security holders by size of holding:

Size of holding	Number of holders	% total shares issued
100,001 and over	271	80.93%
10,001 to 100,000	1,002	15.74%
5,001 to 10,000	526	1.93%
1,001 to 5,000	1,063	1.28%
1 to 1,000	348	0.12%
Totals	3,210	100.00%
Holding less than a marketable parcel	390	0.14%

Equity security holders

Twenty largest quoted equity security holders

The names of the twenty largest security holders of quoted equity securities are listed below:

Holder Name	Number held	% total shares issued
Ocean and Remi Pty Ltd <Cambria Partners A/C>	18,209,955	8.25%
Raymond Demaio Pty Ltd <Raymond Demaio Family A/C>	9,592,000	4.35%
HSBC Custody Nominees (Australia) Limited	9,496,622	4.30%
Emmanuel Investment Holdings Pty Ltd <Loh Family A/C>	6,102,010	2.77%
Burrangong Pty Ltd <Sam Family Settlement A/C>	3,797,101	1.72%
Evergem Pty Ltd <The Evergem Unit A/C>	3,420,000	1.55%
COB Pty Ltd	3,380,000	1.53%
DC Retirement Nominees Pty Ltd <DC Family Trust A/C>	4,523,728	2.05%
J P Morgan Nominees Australia Pty Limited	3,039,320	1.38%
COB Pty Ltd	3,015,546	1.37%
Astro Superannuation Holdings Pty Ltd <Emmanuel Super Fund A/C>	2,865,787	1.30%
Mr Yuk Chung Edward Chiu	2,769,565	1.26%
Mr Paul James Madden	2,671,848	1.21%
Mr Joshua Oliver Stanford-Harris	2,483,466	1.13%
See Breeze Consulting Pty Ltd	2,418,349	1.10%
Carlisle and Co Pty Ltd <Wattle Superfund A/C>	2,300,000	1.04%
Mr John William Bronger	2,140,579	0.97%
Netwealth Investments Limited <Wrap Services A/C>	2,055,366	0.93%
Qintet Pharma Partners Pty Ltd	2,000,000	0.91%
Mrs Aini Loh	1,636,883	0.74%

Unquoted equity securities

Options over ordinary shares issued	Number on Issue	Number of holders
1) <i>Options exercisable at \$0.12c each, expiring 31/03/2026</i> Mersound Pty Ltd, holder of 80% of total issued Fresh Afare Pty Ltd, holder of 20% of total issued	625,000	2
2) <i>Options exercisable at \$0.20c each, expiring 31/03/2026</i> Anna Carina Pty Ltd <Anna Carina Family A/C>, holder of 44.44% of total issued Mersound Pty Ltd, holder of 44.44% of total issued	2,250,000	4
3) <i>Options exercisable at \$0.50c each, expiring 31/03/2026</i> Anna Carina Pty Ltd <Anna Carina Family A/C>, holder of 40% of total issued Mersound Pty Ltd, holder of 40% of total issued	2,500,000	6

Substantial holders

Substantial holders in the company are set out below:

	Ordinary shares	
	Number held	% of total shares issued
Blair Vega Norfolk	18,487,272	8.38%
Douglas Loh	14,190,025	6.43%

Voting rights

The voting rights attached to ordinary shares are set out below:


Ordinary shares

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

There are no other classes of equity securities.

Securities

Class	Expiry date	Number of shares
Ordinary fully paid shares		220,609,231
Unlisted options	31 March 2026	625,000
Unlisted options	31 March 2026	2,250,000
Unlisted options	31 March 2026	2,500,000



Certified



**This company meets the
highest standards of social
and environmental impact**

Corporation

Biome Australia is proud to be a Certified B Corporation since 2021.

Certified B Corporations (B Corps) are for-profit companies that use the power of business to build a more inclusive and sustainable economy. They meet the highest verified standards of social and environmental performance, transparency, and accountability.

The Biome team feels strongly that business can be a force for good. Biome Australia aims to improve not only health outcomes, but be seen as a company working to redefine success in business, demonstrating that inclusivity and sustainability can be part of a healthy economy.

Activated Probiotics® and Activated Therapeutics® are registered trademarks of Biome Australia

Corporate directory

Directors

Geoffrey Sam OAM (Independent Non-Executive Chair)
Blair William Brabin Vega Norfolk (Managing Director)
Dominique Gayle Fisher AM (Independent Non-Executive Director)

Company secretary

George Lazarou

Chief financial officer

Douglas Chee Yong Loh

Registered office

192-194 Johnston Street
Collingwood Victoria 3066
Phone: +61 3 9017 5800

Principal place of business

192-194 Johnston Street
Collingwood Victoria 3066

Share register

Automic Pty Ltd
477 Collins Street
Melbourne Victoria 3000
Phone: 1300 288 664

Auditor

MVAB Assurance
Level 5 North Tower
485 La Trobe Street
Melbourne VIC 3000

Stock exchange listing

Biome Australia Limited shares are listed on the Australian Securities Exchange (ASX code: BIO)

Lawyers

Marque Lawyers Pty Ltd
Level 4, 343 George Street
Sydney NSW 2000

Regulatory Advisor


Anthea Steans Consulting
PO Box 702
Sanctuary Cove QLD 4212

External Accountant and Tax Advisor

MVA Bennett Pty Ltd
Level 5, North Tower
485 Latrobe St
Melbourne VIC 3000

Website

<https://biomeaustralia.com/>



BIOME | AUSTRALIA
GROUP

ACN 627 364 014

192-194 Johnston Street
Collingwood, VIC 3066

P +61 3 9017 5800

biomeaustralia.com